Aspirin Cuts Cancer Risk by 50% in New Study

When Nick James learned he carried a gene that gave him an 80% chance of developing bowel cancer, he became the first person to try something unexpected: a daily aspirin pill.

Ten years later, he remains cancer-free. His story is part of mounting evidence that one of humanity's oldest medicines might also be one of our best defenses against cancer.

Scientists have suspected aspirin's cancer-fighting powers since 1972, when researchers noticed it stopped tumors from spreading in mice. But proving it works in humans required decades of careful study.

The breakthrough came through people like James, who have Lynch Syndrome, a genetic condition that dramatically increases cancer risk. Professor John Burn at Newcastle University led a landmark trial of 861 patients with the condition, tracking them for 10 years.

The results were stunning. Patients who took 600mg of aspirin daily for at least two years cut their cancer risk in half compared to those who didn't take the drug.

These findings are already changing lives. Some countries have updated their medical guidelines to include aspirin as a first line of protection for people at highest risk of colorectal cancer, though doctors stress it should only be taken under medical supervision.

The drug's journey from ancient remedy to modern cancer fighter spans millennia. Clay tablets from Mesopotamia, dating back 4,400 years, describe medicines made from willow tree bark containing compounds similar to modern aspirin. Ancient Egyptians, Greeks, and Romans all used the same remedy.

Scientists are finally understanding how aspirin works its magic against cancer. Its blood-thinning properties, long used to prevent heart attacks and strokes, appear to stop cancer cells from spreading through the body.

Why This Inspires

What makes this discovery so hopeful is its simplicity. While cutting-edge cancer treatments can cost hundreds of thousands of dollars, aspirin costs pennies per pill and is available nearly everywhere on Earth.

Researchers like Professor Anna Martling at Sweden's Karolinska Institute are continuing to study how aspirin can help people who've already had cancer or are genetically susceptible to it. Each new trial brings us closer to understanding exactly who benefits most and at what dose.

For James and thousands of others in the trials, aspirin represents something precious: the ability to take control of their health with a tool that's been helping humanity for thousands of years.

The ancient remedy is proving it still has new tricks to teach us.